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Early detection of breast cancer significantly improves prognosis.
Increasing knowledge of high-risk groups and regular screening
mammography have resulted in an improvement in the rate of
detection of smaller malignant lesions (Arnesson et al, 1995; Tabar
et al, 1995). However, certain minimal mammographic features,
such as small vague densities, indefinable microcalcification or
subtle architectural distortions, alone or in combination, can also
represent non-specific indications of cancerous lesions (Sickles,
1994; Ciatto et al, 1995; Hiatt and Pasick, 1996; Maes et al, 1997).
In addition, the diagnostic accuracy of mammographic screening
in women under 50 with dense breast parenchyma has been ques-
tioned by some authors (Black et al, 1995; Leitch, 1995). For this
reason, uncertain mammographic findings sometimes require
further costly and often uncomfortable investigations, such as
including repeat radiological controls, magnetic resonance
imaging (MRI), positron emission tomography (PET) or invasive
surgical procedures (Ciatto et al, 1995; Harris and Leininger,
1995; Lidbrink et al, 1996; Flanagan et al, 1998; Friedrich, 1998).
A reliable diagnostic marker would therefore be useful to differen-
tiate between women with early-stage breast cancer and women
with benign breast lesions.
Moroz and co-workers identified an isoform of placenta-derived
ferritin consisting of a specific ‘super’ heavy (43-kDa) chain (p43)
(Moroz et al, 1985). This isoferritin has been shown to mediate
immunosuppression during pregnancy (Sirota et al, 1989;
Maymon and Moroz, 1996). Moreover, an elevated p43 level has
been observed in the peripheral blood of patients with Hodgkin’s
disease, AIDS and breast cancer (Moroz et al, 1977, 1989; Rosen
et al, 1992). In an investigation by Moroz involving more than
3000 women, 80% of stage I and II breast cancer patients, but less
than 10% of women with benign breast disease or healthy controls,
had increased p43 expression on lymphocytes, as determined by
radioimmunoassay (Moroz et al, 1989).
So far, only a few studies have examined a possible effect of
p43 expression on the immune system of breast cancer patients,
and thus on its role in the pathomechanism of cancer development
(Bilik et al, 1989; Fargion et al, 1991; Rosen et al, 1996). In-vitro
studies demonstrated the immunosuppressive action of p43 on
lymphocytes (Reinerova et al, 1993; Sedlak et al, 1995).
Our study focused initially on determining the expression of
p43 in a highly selected patient population with uncertain
mammographic findings and non-palpable breast lesions, who
were recruited from a breast cancer screening programme. By
distinguishing between the expression of p43 on CD4+ and CD8+
cells, respectively, in benign and malignant breast lesions, we
sought to identify the lymphocyte subpopulation predominantly
expressing p43.
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Summary Regular screening mammographies and increasing knowledge of high-risk groups have resulted in an improvement in the rate of
detection of smaller malignant lesions. However, uncertain minimal mammographic features frequently require further costly and often
uncomfortable investigation, including repeat radiological controls or surgical procedures, before cancerous lesions can be identified.
Placental isoferritin (p43), a protein with immunosuppressive effects, has been detected on the surface of lymphocytes taken from peripheral
blood in patients with breast cancer. In this study we evaluated the sensitivity and specificity of the expression of p43-positive lymphocytes as
a marker in early stage breast cancer and also investigated its expression on T-cell subpopulations. The presence of p43-positive
lymphocytes was investigated using the monoclonal antibody CM-H-9 and flow cytometry in 76 women with controversial, non-palpable
mammographic findings who were undergoing surgical biopsy. Patients with early breast cancer (n = 48) had significantly higher p43-positive
cell values (median 3.83%, range 0.98–19.4) than patients with benign lumps (n = 28, median 1.43%, range 0.17–3.7) or controls (n = 22,
median 1.3%, range 0.4–1.87) (P < 0.0001). At a cut-off level of 2% p43-positive cells a sensitivity of 91.7% and a specificity of 89.3% for
detection of breast cancer could be reached. While the median ratio of total CD4+/CD8+ cells was 2.6, a ratio of 1.3 was found for the p43-
positive subpopulation (P < 0.001), thus indicating a significant link between p43 and CD8+ cells. The determination of p43-positive
lymphocytes in peripheral blood could serve as an additional diagnostic tool in patients with controversial mammographic findings and could
also reduce the need for cost-intensive and often uncomfortable management of these patients.
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MATERIALS AND METHODS
A total of 76 consecutive female patients were scheduled for
surgical biopsy because of uncertain mammographic findings. All
patients were seen for the first time at a breast cancer clinic at one
of the three participating centres. Inclusion criteria were non-
palpable mammographic lesions in accordance with the character-
istics listed in Table 1. All of these radiological criteria for
potential malignancy had to appear on at least two conventional
mammograms in standard projection (Sickles, 1994; Maes et al,
1997). Diffuse microcalcifications found in mammograms were
eligible if accompanying risk features, such as elongated round or
vermiform microcalcifications, were detected. All mammograms
were reviewed by the reference radiologist (GW), who was
unaware of the results of the histological examination and flow
cytometry. Twenty-two healthy women with normal mammo-
graphic findings served as controls. The study was approved by
the institutional advisory board (ethics committee) of the
University of Vienna Medical School and informed consent was
obtained from all patients before enrolment in the study.
The preoperative localization was determined with a stereotacti-
cally positioned guidewire put in place by the radiologist on the day
of surgery. All biopsy specimens were immediately subjected to
histological analysis in frozen sections and subsequently embedded
in paraffin and stained with haematoxylin and eosin. Histological
grading was performed according to Bloom and Richardson
(1957). With invasive cancer patients, the axillary lymph nodes
(level I and II) were removed. The steroid receptor content was
determined immunohistochemically (Stierer et al, 1995).
Before surgery, 10 ml of EDTA-anticoagulated venous blood
were drawn to determine the lymphocyte count in peripheral blood
(Sysmex NE8000, Toa, Medical Electronics Co. Ltd, Kobe,
Japan). Heparinized peripheral blood was used to separate
lymphocytes for the investigation by flow cytometry.
Table 1 Radiological criteria in mammography
Star-shaped density
Lobulated density
Round density
Spiculated masses and/or clustered microcalcifications
Microcalcifications
Number of microcalcifications > 5 mm–2
Irregularity in size and/or density
Aligned and/or arborescent arrangement
Table 2 Patients’ characteristics, prognostic factors and per cent p43-positive lymphocytes
n Percentage of p43-positive Percentage of p43-positive P-value
lymphocytes (median) lymphocytes (range)
Benign histology 28 1.43 0.17–3.7
Cancer 48 3.83 0.98–19.45 < 0.0001a
DCIS 12 4.33 2.3–19.0
Invasive 36 3.78 0.98–19.45
Lymph node
Negative 33 3.32 0.98–19.45
Positive 15 5.96 1.95–14.03 0.042a
Bloom–Richardson grade
I 14 4.45 2.35–14.03
II 14 3.42 0.98–11.98
III 20 3.31 1.19–19.45 0.108a
ER status
Positive 4 3.76 0.98–19.02
Negative 7 6.55 3.13–19.45 0.068a
PR status
Positive 35 3.81 0.98–14.03
Negative 13 4.29 2.06–19.45 0.210a
Menopausal status
Premenopausal 12 2.85 1.0–19.45
Post-menopausal 36 4.22 0.98–19.02 0.093a
DCIS = ductal carcinoma in situ; ER = oestrogen receptor; PR = progesterone receptor. aWilcoxon rank test.
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Figure 1 Box plot depicting the median, interquartile range, as well as the
minimum and maximum values of p43 (median) on PBMNC of patients with
benign and malignant breast lesions. The median is depicted by the
horizontal bars, the interquartile range by the boxes and the minimum and
maximum values by the vertical bars. Benign: 1.43% (0.17–3.7), cancer:
3.83% (0.98–19.45), P<0.0001, Wilcoxon rank test876 L Auerbach et al
British Journal of Cancer (1999) 80(5/6), 874–878 © Cancer Research Campaign 1999
Flow cytometry
Monoclonal antibodies
The following purified, directly PE and/or PerCP-conjugated mono-
clonal antibodies (mAbs) and their respective isotype-matched
controls were used: LEU-2a (anti-CD8+), LEU-3a (anti-CD4+),
LEU-4 (anti-CD3) and LEU-M3 (anti-CD14) (Becton Dickinson,
Mountain View, CA, USA). The purified mAb CM-H-9, generously
provided by C Moroz, was used for indirect staining with a PE-
labelled secondary antibody (DAKO, Santa Barbara, CA, USA).
Method
Monoclonal and secondary antibodies were titrated for maximum
fluorescent intensity. Surface membrane staining of cells, flow
cytometry and compensation of the FACSort (Becton Dickinson)
were performed as described by other authors (Panzer et al, 1993).
Peripheral blood mononuclear cells (PBMNC) were separated by
Ficoll-Hypaque density centrifugation. Cells were incubated for
25 min with mAb CM-H-9 on ice, washed once and labelled for
another 25 min with the secondary antibody. After a further
washing, the cells were incubated for 20 min with anti-CD14-
FITC and PerCP anti-CD3, or anti-CD4+, or anti-CD8+. After
washing, cells were acquired (30 000 events) using a flow
cytometer and analysed with PAINT-A-GATE software (Becton
Dickinson). Gating by forward-angle versus right-angle light
scatter was performed on the lymphoid window.
Statistical methods
The investigation was performed using the double-blind method,
and the histological results were unknown at the time of determina-
tion by flow cytometry. Non-parametric tests (Mann–Witney U-
test, one-way Kruskal–Wallis non-parametric analysis of variance,
Wilcoxon matched pairs signed ranks test) were used for univariate
comparison of paired parameters. In addition, p43-positive
lymphocytes were calculated at different cut-off levels (2%, 3%,
and 4% positive cells) to evaluate the sensitivity and specificity of
Table 3 Proportion of patients with p43-positive lymphocytes at different cut-off levels in benign and cancer breast lesions
Percentage of p43-positive lymphocytes
n 0–2 2–3 3–4 >4
Benign (28) 25 3 0 0
DCIS (12) 0 2 3 7
Invasive cancer (36) 4 9 7 16
DCIS = ductal carcinoma in situ.
Table 4 Ratio of total CD4+/CD8+ and p43-positive CD4+/p43-positive CD8+
Patients’ characteristics Ratio of CD4+/CD8+ Ratio of p43+CD4+/p43+CD8+ P-value
median (range) median (range)
All patients 2.6 (1.0–9.3) 1.3 (0.2–18.0) < 0.001a
Benign histology 2.8 (1.0–9.3) 1.4 (0.2–9.0) < 0.001a
Cancer 2.4 (1.1–7.8) 1.3 (0.3–18.0) 0.009a
DCIS 2.1 (1.4–4.2) 2.1 (0.3–18.1) 0.720a
Invasive 2.4 (1.1–7.8) 1.3 (0.3–18.0) < 0.001a
DCIS = ductal carcinoma in situ. aWilcoxon rank test.
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Figure 2 Forward and side scatter profile of PBMNC from one representative cancer sample. The lymphoid window for analysis was determined with PAINT-
A-GATE software (A). Three-colour analysis of PBMNC gated for the lymphoid window, CD14 (logarithmic scale) being plotted against side scatter (B).
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this test for prediction of malignancy. The expression of p43 on
CD4+ and CD8+ cells was evaluated by determining the ratio
between CD4+/CD8+ ratio and p43-positive CD4+/p43-positive
CD8+ ratio. A deviation of this ratio from 1 was verified by bino-
mial testing. A significance level of 0.05 was chosen.
RESULTS
Among the 76 patients with uncertain mammographic findings and
non-palpable breast lesions, there were 48 patients with early stage
breast cancer, 12 patients with ductal carcinoma in situ (DCIS) and
36 patients with invasive breast cancer. Twenty-eight patients had a
benign histology. p43-positive cells in controls were < 2% (n = 22,
median 1.3%, range 0.4–1.87). There was a highly significant differ-
ence between p43-positive lymphocytes in patients with malignant
lesions and those in benign breast tissues (P < 0.0001) (Figure 1).
The clinical characteristics and the percentage of lymphocytes
expressing p43 in the two groups are shown in Table 2. No differ-
ence in prognostic factors, such as lymph node status, grading,
menopausal status and steroid receptor status, was observed.
In initial experiments we saw that, among the mononuclear cells,
a large population of CD14+ cells (monocyte macrophage popula-
tion) was stained with the mAb CM-H-9, irrespective of the type of
lesion. Therefore, we carefully gated on the lymphoid window, and
CD14+ cells were removed from the calculation with the aid of the
PAINT-A-GATE software (Figure 2). Subsequently, the expression
of p43 on CD3+ cells and on the CD4+ or CD8+ T-cell subpopula-
tion was determined by triple-colour analysis (Figure 3).
Analysis of the sensitivity and specificity at different cut-off levels
(2%, 3% and 4% p43-positive cells) revealed a sensitivity of 91.7%
and a specificity of 89.3% at 2%, a sensitivity of 68.6% and speci-
ficity of 96.4% at 3%, and a sensitivity of 47.9% and specificity of
100% at 4% p43-positive lymphocytes respectively (Table 3).
Of the three patients with a false positive result at a cut-off level
of 2%, two had a family history of breast cancer in a first-degree
relative. Of the four cancer patients with a p43 result below 2%,
two patients had lymph node-positive and grade III breast cancer,
respectively, while one patient with 1.96% p43-positive cells had
T1a breast cancer.
The ratio among CD4+ and CD8+ cells, p43-positive CD4+ and
p43-positive CD8+ is shown in Table 4. There was no significant
difference between patients with breast cancer and those with
benign lesions. However, the ratio of CD4+/CD8+ was 2.6 (range
1.0–9.3) while the ratio of p43-positive CD4+/p43-positive CD8+
was only 1.3 (range 0.2–18.0) (P < 0.001), thus indicating a signif-
icant association between p43 and CD8+ cells. Of interest, there
was no significant difference between the ratio of CD4+/CD8+
cells and the ratio of p43-positive CD4+/p43-positive CD8+ cells
(P = 0.720) in women with DCIS.
DISCUSSION
In this study we showed that there was a significantly higher expres-
sion of p43 on peripheral lymphocytes in patients with early breast
cancer than in women with benign breast lesions. In the peripheral
blood of patients with early breast cancer the ratio of CD4+/CD8+
and p43-positive cells shifted in favour of the CD8+ subpopulation.
In an earlier investigation of a large patient group of more than
3000 women, Moroz showed that 80% of stage I and II breast
cancer patients had an elevated number of p43-positive lympho-
cytes as determined by radioimmunoassay (Moroz et al, 1989).
These data were confirmed in an unselected group of breast cancer
patients by flow cytometry (Rosen et al, 1993). Our aim was to
determine whether the expression of p43 might serve as a marker
of malignancy in patients with radiologically uncertain findings
and non-palpable breast lesions.
At a cut-off level of 2% p43-positive lymphocytes, we achieved
a sensitivity of 91.7% and a specificity of 89.3%. False negative
p43 values were explained by the presence of highly undifferenti-
ated (grade III) tumours and by lymph node metastases. Likewise,
in 122 patients with breast cancer, the expression of p43 was signif-
icantly higher in tumour cytosols with grade I or low-grade nuclear
pleomorphism than in grade III tumours (Rosen et al, 1992).
We found false positive p43 values in less than 10% of women
with benign breast lesions. In a recent publication by Moroz, long-
term follow-up of false positive women revealed that elevated p43
was a significant predictor of early breast cancer increasing the
normal risk for breast cancer at a factor of about 2.5 (Moroz et al,
1997). It is interesting to note that, in our study, two out of three
patients with a false positive p34 result (at a cut-off level of 2%)
had a family history of breast cancer in a first-degree relative.
Physiologically, the placental production of p43 may play a role
in the prevention or rejection of the embryo by suppression of
maternal lymphocytes (Sirota et al, 1989; Maymon and Moroz,
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Figure 3 Three-colour analysis of PBMNC. Experimental design as in Figure 2. Isotype-matched controls for CM-H-9 (p43-PE) and anti-CD4, CD8 PercP (A).
Expression of p43 on CD4 and CD8 cells (B, C)1996). In line with these in vivo observations, it has been demon-
strated that p43 has suppressing activation on mitogen-induced
lymphocyte proliferation (Fargion et al, 1991). Likewise, increasing
amounts of p43 may also be important for T-cell incompetence in
patients with HIV infection (Moroz et al, 1989b).
The biologic activity of p43 in breast cancer is still not completely
understood. It has been shown that this protein is synthesized by
placenta, breast cancer tissue and activated T-cells (Garty et al, 1995;
Moroz et al, 1997). We can therefore assume that the elevated p43
expression originates from the activated T-cells (reacting against the
cancer) and from malignant cells. Consecutively, p43 may provide
help to the malignancy, either by induction of autoproliferation or by
suppressing anticancer reactive T-cells. The first hypothesis is
currently tested by determination of p43 levels after surgical removal
of the cancer. We expect a decline of p43 expression after surgical
removal.
There is some evidence from our results that, in the CD4+ and
CD8+ T-cell subpopulations, CD8+ cells are the major group
expressing p43 in breast cancer patients. Their activation to
become a cytolytic agent requires help, provided mainly by inter-
leukin 2 (IL-2) from CD4+ cells and autocrine IL-2, and secondary
signalling, via CD2 for example (Bach et al, 1989; Meuer et al,
1983). It is interesting to note that the inhibitory effect of p43 on
T-cells appears to be mediated by masking CD2 (Maymon and
Moroz, 1996; Moroz et al, 1977). The binding of p43 to a partic-
ular subset of CD8+ lymphocytes in patients with invasive tumour,
but not in those with DCIS, suggests that the affected CD8+
subpopulation plays a specific role in the spread of the tumour. We
are focusing now on the characterization of these CD8+ cells to
better understand their role for the tumour biology.
In summary, we have shown that a significantly higher proportion
of p43-positive peripheral blood lymphocytes can be found in women
with early, subclinical breast cancer than in women with benign
breast lesions. The determination of p43 in peripheral blood could
serve as an additional tool in the diagnosis of women who present
with controversial mammographic findings. It could also reduce the
cost of intensive, and often uncomfortable, further investigation.
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